Patent ID: 8628797

Claim:
A sustained release oral dosage form comprising a compressed tablet or caplet core wherein the compressed tablet or caplet core comprises a macrolide antibiotic, a first pharmaceutically acceptable polymer selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose and mixtures thereof in an amount from about 50% or greater by weight of the compressed tablet or caplet core with a viscosity less than 50 cps, and a second pharmaceutically acceptable polymer selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropyl cellulose and mixtures thereof in an amount less than about 5% by weight of the compressed tablet or caplet core with a viscosity greater than 200 cps, wherein the second pharmaceutically acceptable polymer is not 0% by weight of the compressed tablet or caplet core and wherein the first and second pharmaceutically acceptable polymers comprise about 55% or greater by weight of the compressed tablet or caplet core, so that when ingested orally, the composition induces a lower mean fluctuation index in the plasma than an immediate release composition of the macrolide antibiotic while maintaining bioavailability substantially equivalent to that of the immediate release composition of the macrolide antibiotic and the composition does not exhibit a food effect when administered with food.